Nationwide Case Review · 2026
Suffered a Serious GI Injury From Ozempic, Wegovy, or Mounjaro?
Cornerstone Law Can Help.
Thousands of patients who suffered gastroparesis, intestinal obstruction, and severe GI injuries after using Ozempic, Wegovy, Mounjaro, and related drugs are now part of MDL 3094, one of the fastest-growing drug injury MDLs in the country. Bellwether trials are expected in 2027. Cornerstone Law is reviewing cases nationwide — with no upfront cost to you.
GLP-1 drugs like Ozempic, Wegovy, and Mounjaro have exploded in popularity for diabetes and weight loss, but thousands of patients have reported severe gastrointestinal injuries, including gastroparesis (stomach paralysis), intestinal blockage, cyclic vomiting, and pancreatitis. Plaintiffs allege manufacturers knew of these risks and failed to adequately warn patients and prescribers, fueling one of the fastest-growing drug injury MDLs in the country.
MDL 3094
Eastern District of Pennsylvania
1,000s
Cases pending and growing rapidly
2027
Bellwether trials expected
Active
Pharmacovigilance discovery underway
Drugs Involved
Which GLP-1 Drugs Are Part of MDL 3094?
The MDL consolidates claims involving the major GLP-1 receptor agonists currently on the market, manufactured primarily by Novo Nordisk and Eli Lilly. If you were prescribed any of these drugs and suffered a serious GI injury, you may have a claim.
OzempicNovo Nordisk
WegovyNovo Nordisk
MounjaroEli Lilly
ZepboundEli Lilly
RybelsusNovo Nordisk
VictozaNovo Nordisk
Where the MDL Stands
MDL 3094: Phase-by-Phase Status
The court has issued early case-management orders and the parties are deep into discovery. The next major milestone, Daubert challenges on gastroparesis causation, will determine how expert testimony is presented to juries and heavily influence settlement leverage.
Complete
MDL Created
JPML created MDL 3094 in the Eastern District of Pennsylvania in 2024.
Complete
Case Management Orders
Early CMOs issued; preemption and labeling motions largely resolved in plaintiffs' favor.
Active Now
Pharmacovigilance Discovery
Production of internal safety-signal analyses, adverse-event reports, and prescriber depositions underway.
Upcoming
Daubert / Rule 702
Expert battles on gastroparesis and GI motility disorder causation will shape the trial landscape.
Expected 2027
Bellwether Trials
Early test cases will establish case values and drive settlement negotiations.
- Thousands of cases are pending and growing rapidly as more patients connect their GI diagnoses to GLP-1 drug use
- Core failure-to-warn theories remain intact — early motions on preemption and labeling challenges have largely been resolved in plaintiffs' favor
- Plaintiff and prescriber depositions are underway as the early bellwether pool takes shape
Eligibility
Injuries Linked to Ozempic and GLP-1 Drugs
You may qualify if you used Ozempic, Wegovy, Mounjaro, or a related GLP-1 drug and were subsequently diagnosed with a serious gastrointestinal condition. Both patients using these drugs for diabetes management and those using them for weight loss may be eligible.
Qualifying Diagnoses
- Gastroparesis (stomach paralysis)
- Intestinal obstruction or ileus
- Cyclic vomiting syndrome
- Pancreatitis (acute or chronic)
- Gallbladder disease or cholecystitis
- Severe GI motility disorders
General Eligibility Factors
- Prescribed Ozempic, Wegovy, Mounjaro, Zepbound, or related GLP-1 drug
- Used for diabetes management or weight loss
- Developed a qualifying GI diagnosis during or after use
- Diagnosis confirmed and documented by a physician
Daubert rulings will significantly affect case values. Filing now helps ensure your claim is part of the MDL and positioned ahead of the expert battles that will shape the settlement landscape.
Common Questions
What Clients Ask Us Most
I used a compounded version of semaglutide, not the brand-name drug — do I qualify?
Claims against Novo Nordisk and Eli Lilly generally require use of their branded products. Compounded versions raise different legal questions, so it's worth having your specific situation reviewed.
What does it cost to work with Cornerstone Law?
We handle Ozempic and GLP-1 cases on contingency — no upfront fee, and we only get paid if we recover compensation for you.
I stopped taking the drug after my diagnosis — can I still file?
Yes. Stopping the medication doesn't affect your ability to pursue a claim for injuries that already occurred.
Has there been a settlement yet?
Not yet. The MDL is still in discovery, with Daubert challenges and bellwether trials expected in 2027 that will help shape future settlement values.
Why Cornerstone Law: We stay on top of every MDL development, from pharmacovigilance discovery to Daubert rulings to bellwether selections, to ensure our clients receive the strongest possible representation.
Cornerstone Law Is Reviewing Ozempic and GLP-1 Cases Nationwide
We represent patients who suffered serious injuries after using GLP-1 drugs. Find out whether your diagnosis and use history qualify for a claim.
Get a Free Case Review
No fee unless we recover compensation for you. Call 1-800-928-9445.
This page is for informational purposes only and does not constitute legal advice. Prior results do not guarantee a similar outcome in any future case. This is a paid legal advertisement from Cornerstone Law, LLP. Attorney Frank Zeccola, Esq., licensed to practice law in California, is responsible for this advertisement.
